BCMA/CD19 CAR T cell therapy for refractory myasthenia gravis: Proteomic signatures and single-cell transcriptomics of disease flares
Xuzhou Medical College · Tianjin Medical University General Hospital · +3 more institutions
Abstract
Myasthenia gravis (MG) is an autoimmune disorder characterized by B cell dysfunction. Here, we designed B cell maturation antigen (BCMA)/CD19 chimeric antigen receptor T cell (CAR T cell) therapy for six refractory MGs, demonstrating favorable safety with grade 1 cytokine release syndrome observed. CAR T cell expansion induced profound B cell depletion, a sustained reduction in acetylcholine receptor (AChR) antibody titers, and symptom improvement. Five patients achieved drug-free remission with minimal manifestations by month 6, persisting through the 12-month follow-up despite B cell reconstitution. Reconstituted B cells showed naïve predominance with diminished AChR specificity and functional capacities.…
Citation impact
- FWCI
- 107.10
- Percentile
- 100%
- References
- 45
Authors
23Topics & keywords
- Cytokine release syndrome
- T cell
- Myasthenia gravis
- Proinflammatory cytokine
- B cell
- Proteomics
- Refractory (planetary science)
- Chimeric antigen receptor
- Good health and well-being